Overview of Genmab's Share Buyback Program
Genmab A/S has initiated an impressive share buyback program aimed at enhancing shareholder value. The program, announced on March 25, is designed to repurchase up to 2.2 million shares as part of its strategy to reduce capital and fulfill commitments under the Restricted Stock Unit program.
Recent Transactions Under the Buyback Program
The company has executed a series of transactions under this buyback program from May 5 to May 9. These transactions reflect Genmab's ongoing commitment to returning value to its shareholders through effective capital management.
Transactions on May 5, 2025
On May 5, Genmab repurchased a total of 14,083 shares at an average price of DKK 1,430.54, leading to a total value of approximately DKK 20.14 million. These transactions were executed on various trading platforms, including XCSE.
Transactions on May 6, 2025
On the following day, May 6, the company acquired another 13,424 shares at an average price of DKK 1,399.56, resulting in a total expenditure of DKK 18.79 million. This consistent activity shows Genmab's dedication to enhancing shareholder returns.
Transaction Highlights from May 7 to May 9, 2025
Continuing the momentum, on May 7, a significant transaction led to the purchase of 60,000 shares, costing around DKK 82.41 million. The program concluded on May 9 with further acquisitions, which cumulatively brought the total shares repurchased during this period to 72,290 shares for an overall value exceeding DKK 94 million.
Cumulative Program Impact
As of the latest transactions, Genmab holds a total of 179,797 shares through its buyback efforts, amounting to a significant DKK 241.98 million. This systematic approach underscores the company’s strategic vision while thoroughly adhering to the regulations governing share repurchases.
About Genmab
Founded in 1999, Genmab A/S is a biotechnology pioneer headquartered in Copenhagen, Denmark. The company is dedicated to developing innovative antibody therapies designed to improve the lives of patients worldwide. With over 25 years of expertise, it has created groundbreaking technologies that underline its proprietary pipeline, focused primarily on treatments for cancer and serious diseases.
The overarching vision of Genmab is to transform treatment outcomes with its advanced antibody medicines, also known as knock-your-socks-off (KYSO) antibodies. Their unyielding commitment to innovation and collaboration contributes significantly to the biotech landscape.
Future Steps in Capital Management
Moving forward, Genmab will continue to evaluate the success of the share buyback program as part of its broader strategy for shareholder engagement and capital efficiency. By effectively managing its capital resources, Genmab aims not only to bolster shareholder confidence but also to secure its long-term growth narrative.
Frequently Asked Questions
What is the aim of Genmab's share buyback program?
The program is focused on repurchasing shares to enhance shareholder value and support capital management commitments.
How many shares does Genmab intend to repurchase?
Genmab announced plans to repurchase up to 2.2 million shares as part of this buyback program.
What were the total shares acquired during the recent buyback?
During the recent transactions from May 5 to May 9, a total of 72,290 shares were repurchased.
What are knock-your-socks-off (KYSO) antibodies?
KYSO antibodies refer to Genmab's innovative antibody medicines aimed at delivering significant therapeutic benefits, primarily for cancer treatment.
Who can I contact for more information about Genmab?
For inquiries, you can reach out to Marisol Peron or Andrew Carlsen using the provided contact details in the announcement.
